1
|
Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, Dalac Rat S. Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study. J Eur Acad Dermatol Venereol 2024; 38:e71-e73. [PMID: 37595320 DOI: 10.1111/jdv.19435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 08/11/2023] [Indexed: 08/20/2023]
Affiliation(s)
- K Khelef
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - E Maubec
- Service de Dermatologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France
- Campus de Bobigny-Université Sorbonne Paris Nord, Bobigny, France
- UMR 1124, Campus Saint Germain des Prés, Paris, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - B Bonniaud
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - A Pham-Ledard
- Service de Dermatologie, CHU de Bordeaux, Bordeaux, France
- Université de Bordeaux, Bordeaux, France
| | - F Herms
- Service de Dermatologie, Hôpital Saint-Louis, APHP, Paris, France
| | - F Aubin
- Service de Dermatologie, INSERM 1098, CHU de Besançon de Franche Comté, Besançon, France
- Université de Bourgogne-Franche-Comté, Besançon, France
| | - N Beneton
- Service de Dermatologie, CH du Mans, Le Mans, France
| | - M Dinulescu
- Service de Dermatologie, Hôpital Pontchaillou, Rennes, France
| | - A Jannic
- Service de Dermatologie, Hôpital Henri-Mondor, APHP, Créteil, France
| | - A Duval-Modeste
- Service de Dermatologie, Hôpital Charles-Nicolle, Rouen, France
| | - E Archier
- Service de Dermatologie, Hôpital Saint-Joseph, Marseille, France
| | - C Berthin
- Service de Dermatologie, CHU d'Angers, Angers, France
| | - F Grange
- Service de Dermatologie, CHU de Reims, Reims, France
| | - J Arnault
- Service de Dermatologie, CHU Amiens-Picardie, Amiens, France
| | - V Heidelberger
- Service de Dermatologie, CH Robert-Ballanger, Aulnay-sous-Bois, France
| | - M Moncourier
- Service de Dermatologie, CHU de Grenoble-Alpes, Grenoble, France
| | - S Mansard
- Service de Dermatologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - R Triller
- Service de Dermatologie, Institut Franco-Britannique, Levallois-Perret, France
| | - M Pracht
- Groupe Hospitalier de St-Malo, Saint-Malo, France
| | - M Dumas
- Service de Dermatologie, CH René-Dubos, Pontoise, France
| | - O Lauche
- Clinique Clémentville, Montpellier, France
| | - L Mortier
- Service de Dermatologie, CHU de Lille, Lille, France
- INSERM U 1189, Université de Lille, Lille, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - S Dalac Rat
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| |
Collapse
|
2
|
Demarez B, Eté M, David L, Quiles N, Archier E. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma. J Eur Acad Dermatol Venereol 2022; 36:e688-e689. [DOI: 10.1111/jdv.18130] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 02/22/2022] [Accepted: 03/25/2022] [Indexed: 11/28/2022]
Affiliation(s)
- B Demarez
- Dermatologie Hopital Saint Joseph France
| | - M Eté
- Medecine interne Hopital Saint Joseph France
| | - L David
- Dermatologie Hopital Saint Joseph France
| | - N Quiles
- Dermatologie Hopital Saint Joseph France
| | - E Archier
- Dermatologie Hopital Saint Joseph France
| |
Collapse
|
3
|
Fredeau L, Hober C, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval Modeste AB, Cesaire L, Neidhardt EM, Archier E, Dreno B, Lesage C, Berthin C, Kramkimel N, Grange F, De Quatrebarbes J, Stoebner P, Poulalhon N, Arnault J, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Dalac S, Mortier L, Maubec E. Cémiplimab et carcinomes épidermoïdes cutanés localement évolués ou métastatiques : premières données de vie réelle. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Hober C, Fredeau L, Ledard AP, Boubaya M, Herms F, Aubin F, Benetton N, Dinulescu M, Jannic A, Cesaire L, Meyer N, Modeste AD, Archier E, Lesage C, Kramkimel N, Arnault J, Grange F, Dalac S, Mortier L, Maubec E. 1086P Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1210] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
David L, Archier E, Souteyrand A, Beauchet A, Mahé E, Quiles N. Étude HumPso : troubles de l’humeur et psoriasis - Étude des pratiques professionnelles des dermatologues. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
6
|
Larsabal M, Ly S, Sbidian E, Moyal‐Barracco M, Dauendorffer J, Dupin N, Richard M, Chosidow O, Beylot‐Barry M, Abdo I, Acquitter M, Breteque Mignot MA, Amici J, Archier E, Aubin F, Barthelemy H, Baubion E, Beneton N, Bolac C, Bouilly D, Bourseau‐Quetier C, Brenaut E, Buzenet C, Camus M, Celerier P, Chabbert C, Chamaillard M, Charles S, Darrigade A, Delarue M, Depaire F, Devaux S, Do‐Pham G, Duval‐Modeste A, Fabre F, Fauconneau A, Fite C, Fleuret C, Girard C, Grande S, Guillet S, Hacard F, Hegazy S, Hosteing S, Jacquin M, Jegou M, Joly P, Jouary T, Julien D, Kemula M, Kostrzewa E, Lacour J, Legrain V, Livideanu C, Lu D, Maccari F, Magne F, Martin C, Meunier L, Misery L, Parier J, Pelletier F, Perrussel M, Petit‐Fauconneau A, Peyrot I, Plantin P, Pruvost‐Balland C, Regnier E, Reynier‐Rezzi J, Salzes C, Seneschal J, Shollhammer M, Souteyrand A, Staumont D, Toulemonde A, Vanhaecke C, Vedie A, Versapuech J, Vigan M, Viguier M, Villani A. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol 2018; 180:647-656. [DOI: 10.1111/bjd.17147] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/31/2018] [Indexed: 12/01/2022]
Affiliation(s)
- M. Larsabal
- Department of Dermatology Bordeaux University Hospital Bordeaux University Bordeaux France
| | - S. Ly
- Department of Dermatology Bordeaux University Hospital Bordeaux University Bordeaux France
- Vulvology Study Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
| | - E. Sbidian
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Henri‐Mondor Hospital, Public Assistance – Paris Hospitals (AP‐HP) CréteilFrance
- Virus,Immunity and Cancer University‐Hospital Complex (DHU VIC) EA 7379 Epidemiology in Dermatology and Evaluation of Treatments (EpiDermE) Paris‐Est University Créteil (UPEC) CréteilFrance
| | - M. Moyal‐Barracco
- Vulvology Study Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Cochin Tarnier Hospital Paris Descartes University ParisFrance
| | - J.‐N. Dauendorffer
- Vulvology Study Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Saint‐Louis Hospital Paris France
| | - N. Dupin
- Department of Dermatology Cochin Tarnier Hospital Paris Descartes University ParisFrance
- Dermatological Infectiology and Sexually Transmitted Diseases Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
| | - M.A. Richard
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Timone Hospital, Public Assistance–Marseille Hospitals Aix‐Marseille University UMR 911, INSERM CRO2, “Centre de recherche en oncologie biologique et oncopharmacologie” Marseille France
| | - O. Chosidow
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Henri‐Mondor Hospital, Public Assistance – Paris Hospitals (AP‐HP) CréteilFrance
- Virus,Immunity and Cancer University‐Hospital Complex (DHU VIC) EA 7379 Epidemiology in Dermatology and Evaluation of Treatments (EpiDermE) Paris‐Est University Créteil (UPEC) CréteilFrance
- Dermatological Infectiology and Sexually Transmitted Diseases Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
| | - M. Beylot‐Barry
- Department of Dermatology Bordeaux University Hospital Bordeaux University Bordeaux France
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Gillard M, Archier E, Monnet O, Souteyrand A, Turner F, Gras R, Quiles-Tsimaratos N. [Cutaneous foreign body granulomas following cervico-facial arterial embolization: Three cases]. Ann Dermatol Venereol 2018; 145:659-664. [PMID: 30217682 DOI: 10.1016/j.annder.2018.07.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Revised: 02/08/2018] [Accepted: 07/13/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND Foreign body granuloma is an inflammatory tissue reaction to exogenous material. Classically it appears on the face after aesthetic procedures. Herein we report for the first time three cases of facial granulomatous reactions to microbeads after arterial cervico-facial embolization. PATIENTS AND METHODS Three patients underwent embolization of the facial arteries using Embogold® microbeads in a setting of epistaxis or tumoral hemostasis. Within 10 to 45 days painful, inflammatory, subcutaneous nodules appeared on the homolateral side of the face. Histological samples showed an inflammatory response with giant cells as well as the presence of microbeads in the skin. A favorable outcome was achieved with colchicine in one patient and with surgery in another; the third patient was lost to follow-up. DISCUSSION The embolizing microspheres produced a local inflammatory reaction, with destruction of the vascular wall and bead migration to facial tissue leading to a granulomatous reaction. The occurrence of three cases within a period of few weeks, with several different operators and batches of products, is surprising considering the long-standing use of the product. There was no common comorbidity in the patients and no suggestion of trauma. Retrospective analysis of the product batches was normal. Gold staining could play a role in severe inflammatory response to Embogold® particles. CONCLUSION These three cases illustrate the value of discussing potential foreign body granulomatous reaction in cases of facial nodules following cervico-facial embolization. Colchicine may offer a valuable therapeutic alternative.
Collapse
Affiliation(s)
- M Gillard
- Service de dermatologie, hôpital Saint-Joseph, 26, boulevard de Louvain, 13285 Marseille, France.
| | - E Archier
- Service de dermatologie, hôpital Saint-Joseph, 26, boulevard de Louvain, 13285 Marseille, France
| | - O Monnet
- Service de radiologie interventionnelle, hôpital Saint-Joseph, 26, boulevard de Louvain, 13285 Marseille, France
| | - A Souteyrand
- Service de dermatologie, hôpital Saint-Joseph, 26, boulevard de Louvain, 13285 Marseille, France
| | - F Turner
- Service de chirurgie ORL, hôpital Saint-Joseph, 26, boulevard de Louvain, 13285 Marseille, France
| | - R Gras
- Service de chirurgie ORL, hôpital Saint-Joseph, 26, boulevard de Louvain, 13285 Marseille, France
| | - N Quiles-Tsimaratos
- Service de dermatologie, hôpital Saint-Joseph, 26, boulevard de Louvain, 13285 Marseille, France
| |
Collapse
|
8
|
Gillard M, Archier E, Monnet O, Souteyrand A, Turner F, Gras R, Tsimaratos NQ. Granulomes cutanés à corps étrangers après embolisation artérielle de la sphère ORL : à propos de trois cas. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Archier E, Reynier-Rezzi J, Souteyrand A, Quiles N. Hyperpigmentation faciale sous dénosumab. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, Richard MA, Regis J, Grob JJ. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 2014; 25:2086-2091. [PMID: 25057167 DOI: 10.1093/annonc/mdu266] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Both Gamma-Knife radiosurgery (GKRS) and BRAF inhibitors (BRAF-I) have been shown to be useful in melanoma patients with brain metastases (BMs), thus suggesting that it could be interesting to combine their respective advantages. However, cases of radiosensitization following conventional radiation therapy in BRAF-I treated patients have raised serious concerns about the real feasibility and risk/benefit ratio of this combination. PATIENTS AND METHODS Review by two independent observers of brain magnetic resonance imaging (MRI) follow-up pictures, and volume and edema quantifications, and survival assessment in all patients who had been treated by GKRS and BRAF-I at a single institution. RESULTS Among 53 GKRS carried out in 30 patients who ever received BRAF-I and GKRS, 33 GKRS were carried out in 24 patients while under BRAF-I treatment, from which only 4 with an interruption of BRAF-I. The 20 other GKRS were carried out in 15 patients (including 9 of the 24) before initiation of BRAF-I treatment. No case of radiation-induced necrosis and no scalp radiation dermatitis occurred. A >20% increase in volume was observed in 35 of the 263 BM treated by GKRS (13.3%), but only 3 clear-cut edemas and 3 hemorrhages were detected within 2 months after GKRS, and 4 edemas and 7 hemorrhages later. Neither the MRI features nor the incidence of the volume changes, hemorrhage and edema were deemed unexpected for melanoma BM treated by GKRS. Median survival from first GKRS under BRAF-I and first dose of BRAF-I were 24.8 and 48.8 weeks, respectively. CONCLUSION This series does not show immediate radiotoxicity nor radiation recall, in melanoma patients with BRAF-I whose BMs are treated by GKRS. Interrupting BRAF-I for stereotactic radiosurgery (SRS) of BM seems useless, although it is still advised for other radiation therapies. The potential benefit of combining SRS and BRAF-I can be safely tested.
Collapse
Affiliation(s)
| | - R Carron
- Department of Stereotaxic and Functional Neurosurgery, Gammaknife Unit, Inserm U751
| | - C Delsanti
- Department of Stereotaxic and Functional Neurosurgery, Gammaknife Unit, Inserm U751
| | - A Loundou
- Department of Public Health, Aix-Marseille University, APHM, Marseille, France
| | - S Monestier
- Department of Dermatology and Skin Cancers, UMR911 CRO2
| | - E Archier
- Department of Dermatology and Skin Cancers, UMR911 CRO2
| | - M A Richard
- Department of Dermatology and Skin Cancers, UMR911 CRO2
| | - J Regis
- Department of Stereotaxic and Functional Neurosurgery, Gammaknife Unit, Inserm U751
| | - J J Grob
- Department of Dermatology and Skin Cancers, UMR911 CRO2
| |
Collapse
|
11
|
Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, Richard MA, Regis J, Grob JJ. On-demand Gamma Knife combined with BRAF inhibitors for the treatment of melanoma brain metastases. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Caroline Gaudy-Marqueste
- Dermatology and skin cancers Department, UMR911 CRO2 Hôpital Timone, Aix Marseille University, Marseille, France
| | - Romain Carron
- Department of Stereotaxic and Functional Neurosurgery, Gammaknife Unit, Inserm U751, Aix-Marseille University, APHM, Marseille, France
| | - Christine Delsanti
- Department of Stereotaxic and Functional Neurosurgery, Gammaknife Unit, Inserm U751, Aix-Marseille University, APHM, Marseille, France
| | - Anderson Loundou
- Public Health Department Aix-Marseille University, APHM, Marseille, France, Marseille, France
| | - Sandrine Monestier
- Dermatology and Skin Cancers Department, UMR911 CRO2 Hopital Timone, Aix-Marseille University, Marseille, France
| | - Elodie Archier
- Dermatology and Skin Cancers Department, UMR911 CRO2, Aix-Marseille University, APHM, Marseille, France
| | - Marie-Aleth Richard
- Dermatology and Skin Cancers Department, UMR911 CRO2 Timone Hospital, Aix-Marseille University, Marseille, France
| | - Jean Regis
- Department of Stereotaxic and Functional Neurosurgery, Gammaknife Unit, Inserm U751, Aix-Marseille University, APHM, Marseille, France
| | - Jean-Jacques Grob
- Dermatology and Skin Cancers Department, UMR911 CRO2 Aix-Marseille University, APHM, Marseille, France
| |
Collapse
|
12
|
Gaudy-Marqueste C, Archier E, Grob A, Durieux O, Loundou A, Richard MA, Grob JJ. Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. Eur J Cancer 2014; 50:1120-4. [DOI: 10.1016/j.ejca.2013.12.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Revised: 11/22/2013] [Accepted: 12/15/2013] [Indexed: 10/25/2022]
|
13
|
Mallet S, Ranque S, Amatore F, Archier E, Gaudy C, Monestier S, Hesse S, Grob JJ, Richard MA. Investigation et gestion d’une épidémie de teigne à la crèche d’un hôpital. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
14
|
Troin L, Archier E, Gaudy C, Bruneu Y, Grob J, Richard M. Pemphigoïde bulleuse au cours du traitement par gliptines : trois cas. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Gaudy-Marqueste C, Carron R, Archier E, Mallet S, Monestier S, Richard MA, Grob JJ. Radiochirurgie stéréotaxique et B-RAF inhibiteurs dans les métastases cérébrales de mélanome. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Gaudy-Marqueste C, Levy-Bencheton A, Monestier S, Mallet S, Archier E, Ouafik L, Richard MA, Grob JJ. Carcinome épidermoïde vulvaire sous vemurafenib. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Troin L, Monestier S, Archier E, Richard MA, Gaudy-Marqueste C, Levy-Bencheton A, Grob JJ. DRESS sous vemurafenib : une bonne indication du dabrafenib ? Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Dussouil ASL, Gaudy C, Archier E, Bigand E, Regis JM, Grob JJ, Richard MA. Alopécie circonscrite après radio neurochirurgie interventionnelle. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, Jullien D, Aubin F, Bachelez H, Joly P, Le Maître M, Misery L, Richard MA, Paul C, Ortonne JP. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:36-46. [PMID: 22512679 DOI: 10.1111/j.1468-3083.2012.04522.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Topical steroids are used for more than 50 years to treat mild-to-moderate plaque psoriasis. The purpose of this systematic review was to evaluate the efficacy but also the optimal modalities of administration of topical corticosteroids in psoriasis i.e. influence of steroid potency on clinical response, putative impact of topical formulation, occlusion procedure, rate of application to control the initial response and the potential interest of a maintenance treatment to prolong psoriasis clearance. MATERIAL AND METHODS A systematic search was performed between 1980 and January 2011 in Medline, Embase and Cochrane databases (English and French language, adults), using the keywords 'psoriasis'/exp/mj AND 'corticosteroid'/exp/mj. To analyse response across studies, three levels of response were categorized depending on the data available in studies: percentage of patients who achieved more than 50%, 75% or 90% improvement of initial psoriasis severity. RESULTS From an initial selection of 1269 references, 1166 references were excluded on reading the title or the abstract and 32 on reading the article and 71 were finally retained and analysed. Fifty randomized controlled trials (RCT) assessing topical steroids in the initial treatment of mild-to-severe psoriasis body plaque psoriasis were retained: 40 were parallel-group studies and 10 were within-patient studies. Treatment duration was mostly 4 weeks. Sample size varied from 30 to 1 603 patients. Outcome measures to assess efficacy were highly variable. A total of 30-90% patients across parallel group studies experienced more than 50% of initial mild-to-severe psoriasis improvement while from 7% to 85% experienced more than 75% improvement and from 5% to 85% experienced at least 90% of improvement. The success rate in the within-patient studies varied from 10% to 70%. Eighteen RCT were performed in scalp psoriasis: 16 were parallel-group and two were within-patient studies, with a treatment follow-up time from 2 weeks to 6 months, enrolling 42-1417 patients. A total from 40% to 75% patients across studies experienced more than 75% of initial scalp psoriasis improvement and from 43% to 90% experienced more than 90% initial psoriasis improvement. Only three RCT studies evaluated topical steroids as a maintenance treatment for body psoriasis and one for scalp lesions. Despite heterogeneity in treatment schedule, topical steroid intermittent maintenance treatment was shown to prolong remission. The literature analysis did not provide with high evidence-based quality data on the role of formulation, topical steroid potency, number of applications per day to obtain the highest rate of success excepting occlusion dressing which provided with additional benefit. CONCLUSION The clinical development of topical steroids in psoriasis did not follow state of the art modern methodology. Treatment success appears to be highly variable across studies. Maintenance intermittent treatment appears to be useful to prolong remission. Recommendations concerning topical steroids treatment modalities in plaque psoriasis should be mostly based on expert opinion.
Collapse
Affiliation(s)
- E Castela
- Dermatology Department, Nice University, L'Archet II Hospital, Nice, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, Aractingi S, Aubin F, Bachelez H, Cribier B, Jullien D, Le Maître M, Richard MA, Ortonne JP, Paul C. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:61-7. [PMID: 22512682 DOI: 10.1111/j.1468-3083.2012.04525.x] [Citation(s) in RCA: 134] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Treatment adherence has been recognized as an important issue in the management of chronic diseases such as psoriasis. OBJECTIVE The aim of this work was to analyse data about topical treatment adherence in psoriasis. METHODS Systematic literature review (62 references) between 1980 and 2011 (database: PubMed, Embase and Cochrane; Mesh keywords: Patient Compliance [Mesh] OR Medication Adherence [Mesh] AND Psoriasis [Mesh]; limits: date of publication >1980, humans subjects, written in French or English, aged ≥ 19 years). Two parameters were evaluated: (i) the ratio of number of product applications performed vs. number of applications expected according to physician recommendations, (ii) the ratio of amount of product used vs. amount of product prescribed. RESULTS A total of 22 studies were selected. Nine studies reported on the frequency of topical treatment application in a real world setting. Five studies showed a frequency of applications varying between 50% and 60% of those expected. Because of the high variability in medication adherence assessment methods, the data could not be combined. Twelve articles reported on the frequency of topical treatment application in randomized controlled trials with adherence varying between 55% and 100%. Concerning the amount of product use, four studies showed patients applied between 35% and 72% of the recommended dose during a treatment period of 14 days to 8 weeks. The most frequently mentioned reasons for non-adherence to topical treatment were low efficacy, time consumption and poor cosmetic characteristics of topical agents. Patients experiencing adherence issues were significant younger, were men, had younger age at onset of psoriasis and had a higher self-assessed severity. To improve adherence, the following strategies were suggested: to give patients information about psoriasis, to recognize social impact, to give written instructions for use such as a care plan, to explain side effects of topical therapies, to choose treatment and its cosmetic properties in agreement with the patient. CONCLUSIONS Literature data about topical treatment adherence are heterogeneous and scarce. They confirm the limited topical treatment adherence in psoriasis in real life, much lower than what is reported in randomized controlled trials. Therapeutic education and clear instructions on the use of topical agents are necessary to improve adherence. Studies are needed to identify predictors of limited adherence and to identify interventions improving adherence to topical medications in psoriasis.
Collapse
Affiliation(s)
- S Devaux
- Dermatology Department, Paul Sabatier University, Toulouse, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, Jullien D, Aubin F, Bachelez H, Joly P, Le Maître M, Misery L, Richard MA, Paul C, Ortonne JP. Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:47-51. [PMID: 22512680 DOI: 10.1111/j.1468-3083.2012.04523.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Topical steroids have been used for more than 50 years in mild-to-moderate plaque psoriasis and carry a theoretical risk of adverse events. OBJECTIVES The aim of this systematic literature review was to evaluate the risk of hypothalamo-pituitary-adrenal (HPA) axis suppression and the risk of skin atrophy with topical steroids in the treatment of plaque psoriasis. METHODS A systematic search between 1980 and January 2011 in Medline, Embase and Cochrane databases (English, French language, adults), using the keywords 'psoriasis'/exp/mj AND 'corticosteroid'/exp/mj, RESULTS Altogether 1269 references were found. Of these 1124 articles were excluded by reading the abstract and 123 by reading the article. A total of 22 randomized trials were selected. Effects on HPA axis: Thirteen studies, with a sample size varying from 7 to 341 patients, were selected. The effect on HPA axis was evaluated by the morning cortisol level (11 studies), the 24 h urine steroid levels (five studies) and/or by the Synacthen test (three studies). Reduction of morning cortisol was observed in 0-25% of patients in 10 short-term studies (two in scalp psoriasis, eight in body psoriasis) and in 48% of patients in the remaining short-term study (body psoriasis). Only four of these studies with three on body psoriasis evaluated the effect of long-term treatment defined as 6-month treatment duration or longer and did not identify HPA axis suppression by cortisol level measurement. The Synacthen test, considered as the gold standard to assess HPA axis, was always normal. There was no evidence of clinically significant HPA axis suppression due to absorption of topical steroids even when treating the scalp or in patients with extensive disease. Risk of skin atrophy: Thirteen studies with topical steroid evaluating treatment durations from 4 weeks to 1 year were analysed. The frequency of skin atrophy assessed clinically, varied from 0% to 5% of patients. CONCLUSIONS The literature analysis on topical steroids in psoriasis is reassuring although the quality of safety studies is limited with a majority of short-term studies. Although short-term biological effects of topical steroids on the HPA axis were observed in several clinical studies, they were not associated with clinical signs. Adequately designed long-term studies would be necessary to better determine the risk of skin atrophy using modern methods of evaluation such as dermoscopy and echography.
Collapse
Affiliation(s)
- E Castela
- Dermatology Department, Nice University, L'Archet II Hospital, Nice, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne J, Richard M. Ocular damage in patients with psoriasis treated by Psoralen UV-A therapy or Narrow band UVB therapy: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:32-5. [DOI: 10.1111/j.1468-3083.2012.04521.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA. Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:22-31. [DOI: 10.1111/j.1468-3083.2012.04520.x] [Citation(s) in RCA: 195] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
24
|
Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA. Efficacy of Psoralen UV-A therapy vs. Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:11-21. [DOI: 10.1111/j.1468-3083.2012.04519.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, Aractingi S, Aubin F, Bachelez H, Cribier B, Jullien D, Le Maître M, Richard MA, Ortonne JP, Paul C. Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:52-60. [DOI: 10.1111/j.1468-3083.2012.04524.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Paul C, Gallini A, Archier E, Castela E, Devaux S, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Maître M, Misery L, Richard MA, Ortonne JP. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:1-10. [DOI: 10.1111/j.1468-3083.2012.04518.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Castela E, Gallini A, Archier E, Devaux S, Paul C, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Maître M, Misery L, Richard MA, Ortonne J. Risque de freination de l’axe surrénalien et d’atrophie cutanée sous dermocorticoïdes dans le psoriasis de l’adulte : analyse systématique de la littérature. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.09.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
28
|
Quentel G, Archier E, Solignac J, Coscas G. [Osteoma or choroidal calcification?]. Bull Soc Ophtalmol Fr 1982; 82:481-4. [PMID: 7105346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|